Related Articles
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
Clinical outcomes and influencing factors of PD‑1/PD‑L1 in hepatocellular carcinoma (Review)
A metabolomic and proteomic study to elucidate the molecular mechanisms of immunotherapy resistance in patients with oesophageal squamous cell carcinoma
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy